Ofirmev sales are expected to be driven by strong demand, as customers focus on non-opioid or multimodal pain management. We also expect the company to throw more light on its business separation plan. In December 2018, the company announced that it intends to spin-off the Specialty Generics/Active Pharmaceutical Ingredients business along with Amitiza into a new company. The spin-off will be completed by the second half of 2019 and will result in two separate, publicly-traded companies.